SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Spironolactone and Hydrochlorothiazide Tablets

Trade Name: Aldactazide; Aldactone HCT; Aldazida; Aldactazida
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antihypertensive, diuretic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Carcinogenicity: Category 2

Label Elements

Signal Word: Danger
Hazard Statements: H360D - May damage the unborn child
H351 - Suspected of causing cancer

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Iron oxide	1309-37-1	215-168-2	Not Listed	*
Hydrochlorothiazide	58-93-5	200-403-3	Not Listed	>1
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Calcium sulfate, dihydrate	10101-41-4	Not Listed	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	*
Spironolactone	52-01-7	200-133-6	Carc.2 (H351) STOT RE.2 (H373) Repr.1B (H360D)	<10
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Flavor	NOT ASSIGNED	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	*

Additional Information: *** per tablet/capsule/lozenge/suppository
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Toxic or corrosive gases including oxides of carbon and oxides of sulfur

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Iron oxide

ACGIH Threshold Limit Value (TWA)	5 mg/m^3
Australia TWA	5 mg/m^3
	10 mg/m^3
Austria OEL - MAKs	5 mg/m^3
	10 mg/m^3
Belgium OEL - TWA	5 mg/m^3
Bulgaria OEL - TWA	5.0 mg/m^3
Denmark OEL - TWA	3.5 mg/m^3
Estonia OEL - TWA	3.5 mg/m^3
Finland OEL - TWA	5 mg/m^3
France OEL - TWA	5 mg/m^3
Greece OEL - TWA	10 mg/m^3
Hungary OEL - TWA	6 mg/m^3
Ireland OEL - TWAs	5 mg/m^3
	10 mg/m^3
	4 mg/m^3
Lithuania OEL - TWA	3.5 mg/m^3
OSHA - Final PELS - TWAs:	10 mg/m^3
	15 mg/m^3
Poland OEL - TWA	5 mg/m^3
Portugal OEL - TWA	5 mg/m^3
Romania OEL - TWA	5 mg/m^3
Russia OEL - TWA	6 mg/m^3
Slovakia OEL - TWA	1.5 mg/m^3
Spain OEL - TWA	5 mg/m^3
Sweden OEL - TWAs	3.5 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3
Vietnam OEL - TWAs	5 mg/m^3

Hydrochlorothiazide

Pfizer OEL TWA-8 Hr:	250µg/m^3

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Austria OEL - MAKs	5 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Bulgaria OEL - TWA	10.0 mg/m^3
Denmark OEL - TWA	6 mg/m^3
Estonia OEL - TWA	5 mg/m^3
France OEL - TWA	10 mg/m^3
Greece OEL - TWA	10 mg/m^3
	5 mg/m^3
Ireland OEL - TWAs	10 mg/m^3
	4 mg/m^3
Latvia OEL - TWA	10 mg/m^3
Lithuania OEL - TWA	5 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELS - TWAs:	15 mg/m^3
Poland OEL - TWA	10.0 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Romania OEL - TWA	10 mg/m^3
Russia OEL - TWA	10 mg/m^3
Spain OEL - TWA	10 mg/m^3
Sweden OEL - TWAs	5 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3
Vietnam OEL - TWAs	6 mg/m^3 5 mg/m^3

Calcium sulfate, dihydrate

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Germany (DFG) - MAK	1.5 mg/m^3 4 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Spain OEL - TWA	10 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3
Vietnam OEL - TWAs	6 mg/m^3

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Bulgaria OEL - TWA	10.0 mg/m^3
Czech Republic OEL - TWA	4.0 mg/m^3
Greece OEL - TWA	10 mg/m^3 5 mg/m^3
Ireland OEL - TWAs	10 mg/m^3 4 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Slovakia OEL - TWA	4 mg/m^3
Spain OEL - TWA	10 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3

Spironolactone

Pfizer OEL TWA-8 Hr:	90 µg/m^3, Skin

Magnesium stearate

Lithuania OEL - TWA	5 mg/m^3
Sweden OEL - TWAs	5 mg/m^3

Polyethylene glycol

Austria OEL - MAKs	1000 mg/m^3
Germany - TRGS 900 - TWAs	1000 mg/m^3
Germany (DFG) - MAK	1000 mg/m^3 average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m^3
Slovenia OEL - TWA	1000 mg/m^3
Switzerland OEL -TWAs	1000 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls:	General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Hands:	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Film-coated tablets	**Color:**	Tan
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Povidone
No data available

Magnesium stearate
No data available

Corn Starch
No data available

Hydroxypropyl cellulose
No data available

Iron oxide
No data available

Titanium dioxide
No data available

Hydroxypropyl methylcellulose
No data available

Polyethylene glycol
No data available

Flavor

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Calcium sulfate, dihydrate

No data available

Spironolactone

Predicted 7.4 Log D 3.12

Hydrochlorothiazide

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: Antihypertensive drug: has blood pressure-lowering properties
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood, kidneys, reproductive system.
Known Clinical Effects: Signs and symptoms might include nausea, vomiting, cramps, dizziness, headache, vertigo, low blood pressure on standing, rash, urticaria, photosensitivity, electrolyte imbalance, muscle spasm, weakness, and restlessness. Hypersensitivity reactions may also occur in susceptible individuals. Effects on blood and blood-forming organs have also occurred. May cause adverse effects on the developing fetus.

Acute Toxicity: (Species, Route, End Point, Dose)

Povidone

Rat Oral LD50 100 g/kg

11. TOXICOLOGICAL INFORMATION

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m^3

Titanium dioxide
Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

Spironolactone
Rat Oral LD 50 4121 mg/kg
Mouse Oral LD 50 >1000mg/kg
Rabbit Oral LD 50 >1000mg/kg
Rat Intraperitoneal LD 50 786mg/kg

Hydrochlorothiazide
Rat Oral LD 50 2750 mg/kg
Mouse Oral LD 50 2830mg/kg
Rat Intravenous LD 50 990mg/kg
Dog Intravenous LD 50 250mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Polyethylene glycol
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Spironolactone
Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Spironolactone
13 Week(s) Rat Oral 50 mg/kg LOAEL Blood
78 Week(s) Rat Oral 50 mg/kg/day LOAEL Liver, Male reproductive system

Hydrochlorothiazide
30 Day(s) Rat Oral 1 g/kg/day LOAEL Blood
13 Week(s) Mouse Oral 12,500 ppm LOAEL Bladder
9 Month(s) Dog Oral 50 mg/kg/day LOAEL Endocrine system
1 Year(s) Rat Oral 2000 ppm LOAEL Kidney
2 Year(s) Rat Oral 250 ppm LOAEL Kidney

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

11. TOXICOLOGICAL INFORMATION

Spironolactone
Reproductive & Fertility Rat Oral 15 mg/kg/day NOAEL Fetotoxicity
Reproductive & Fertility Rat Intraperitoneal 100 mg/kg/day LOAEL Fertility
Embryo / Fetal Development Mouse Intraperitoneal 100 mg/kg/day LOAEL Maternal Toxicity
Embryo / Fetal Development Rat Oral 50 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rabbit Oral 20 mg/kg/day LOAEL Fetotoxicity

Hydrochlorothiazide
Reproductive & Fertility Rat Oral 1000 mg/kg LOAEL Maternal toxicity
Reproductive & Fertility Mouse Oral 3000 mg/kg/day NOEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOEL Not Teratogenic
Embryo / Fetal Development Mouse Oral 3000 mg/kg/day NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Spironolactone
Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative
Mammalian Cell Mutagenicity Negative without activation

Hydrochlorothiazide
Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Positive
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative
Dominant Lethal Assay Drosophila Negative
Mammalian Cell Mutagenicity Mouse Lymphoma Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Spironolactone
104 Week(s) Rat Oral 10 mg/kg/day LOAEL Benign tumors
52 Week(s) Non-human Primate Oral 20 mg/kg/day LOAEL Reproductive System

Hydrochlorothiazide
2 Year(s) Rat Oral 2000 ppm NOAEL Not carcinogenic
2 Year(s) Female Mouse Oral 5000 ppm NOAEL Not carcinogenic
2 Year(s) Male Mouse Oral 5000 ppm LOAEL Malignant tumors, Liver

Carcinogen Status: See below

Povidone
IARC: Group 3 (Not Classifiable)

Iron oxide
IARC: Group 3 (Not Classifiable)

Titanium dioxide
IARC: Group 2B (Possibly Carcinogenic to Humans)

Spironolactone
IARC: Group 3 (Not Classifiable)

11. TOXICOLOGICAL INFORMATION

Hydrochlorothiazide
IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Spironolactone
Predicted 7.4 Log D 3.12

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

15. REGULATORY INFORMATION

Iron oxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-168-2

Flavor

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Povidone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Hydrochlorothiazide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-403-3

Hydroxypropyl cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 9/2/2011 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	236-675-5

Calcium sulfate, dihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Spironolactone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 5/1/1997
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-133-6

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Polyethylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 3
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection.
Revision date:	07-Aug-2018
	Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet